Unresectable Malignant Pleural Mesothelioma (MPM)

Also known as: Malignant Pleural Mesothelioma, Unresectable

Drug	Drug Name	Drug Description
DB06186	Ipilimumab	A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
DB09035	Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB00642	Pemetrexed	A folate analog used to treat mesothelioma and non-small cell lung cancer.

Drug	Drug Name	Target	Type
DB06186	Ipilimumab	Cytotoxic T-lymphocyte protein 4	target
DB09035	Nivolumab	Programmed cell death protein 1	target
DB09035	Nivolumab	Programmed cell death 1 ligand 1	target
DB00642	Pemetrexed	Thymidylate synthase	target
DB00642	Pemetrexed	Dihydrofolate reductase	target
DB00642	Pemetrexed	Trifunctional purine biosynthetic protein adenosine-3	target
DB00642	Pemetrexed	Deoxycytidine kinase	enzyme
DB00642	Pemetrexed	Bifunctional purine biosynthesis protein PURH	target
DB00642	Pemetrexed	Equilibrative nucleoside transporter 1	enzyme
DB00642	Pemetrexed	Solute carrier family 22 member 8	transporter
DB00642	Pemetrexed	Folate transporter 1	transporter
DB00642	Pemetrexed	Proton-coupled folate transporter	transporter
DB00642	Pemetrexed	ATP-binding cassette sub-family G member 2	transporter
DB00642	Pemetrexed	Multidrug resistance-associated protein 5	transporter
DB00642	Pemetrexed	Solute carrier family 22 member 6	transporter
DB00642	Pemetrexed	Serum albumin	carrier
DB00642	Pemetrexed	Solute carrier family 22 member 11	transporter

Drug	Drug Name	Phase	Status	Count
DB11595	Atezolizumab	2	Withdrawn	1